Cancers, Vol. 15, Pages 5846: Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study
idis
Evangelos Terpos
Newer methodologies are needed to assess the real-world comparative effectiveness of a “generation” of pharmaceutical innovation versus the prior standard of care. This chart review study aimed to first evaluate the cumulative clinical benefits of pharmaceutical innovation in everyday relapse/refractory multiple myeloma before analyzing findings in the context of respective real-world outcomes from the bortezomib/lenalidomide era. Study endpoints included the 52-week PFS rate in second and third line of therapy (LOT), mPFS-2 across the first and second LOT, the ORR, r...
Source: Cancers - December 14, 2023 Category: Cancer & Oncology Authors: Ioannis Petrakis Christos Kontogiorgis Evangelia Nena Sosana Delimpasi Natasa E. Loutsidi Emmanouil Spanoudakis Stergios Intzes Christina Misidou Marianthi Symeonidou Nikolaos Giannakoulas Theodoros C. Constantinidis Evangelos Terpos Tags: Article Source Type: research
Clinical characteristics and prognosis in patients with neuronal surface antibody-mediated autoimmune encephalitis: a single-center cohort study in China
ConclusionsDifferent AE subtypes demonstrated different clinical symptom spectra throughout the disease stage. Anti-LGI1 encephalitis and anti-CASPR2 encephalitis were more sensitive to first-line and second-line treatments. Anti-GABABR encephalitis had the worst prognosis among the abovementioned subtypes. The regression equation constructed using NLR and tumour presence effectively predicted the poor prognosis. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - December 12, 2023 Category: Allergy & Immunology Source Type: research
BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma
Blood Cancer Journal, Published online: 11 December 2023; doi:10.1038/s41408-023-00955-yBCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - December 11, 2023 Category: Hematology Authors: Debasmita Dutta Jiye Liu Kenneth Wen Keiji Kurata Mariateresa Fulciniti Annamaria Gulla Teru Hideshima Kenneth C. Anderson Source Type: research
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
CONCLUSION: Frail patients treated with PVd demonstrated a higher ORR and a longer PFS and DoT vs. Vd, despite a higher frequency of grade ≥ 3 TEAEs leading to pomalidomide, bortezomib, and/or dexamethasone discontinuation. Therefore, PVd treatment may improve patient outcomes, regardless of frailty.PMID:38072743 | DOI:10.1016/j.clml.2023.10.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 10, 2023 Category: Cancer & Oncology Authors: Albert Oriol Meletios Dimopoulos Fredrik Schjesvold Meral Beksac Thierry Facon Sujith Dhanasiri Shien Guo Yutian Mu Kevin Hong Christian Gentili Monica Galli Munci Yagci Alessandra Larocca Paul Richardson Katja Weisel Source Type: research
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
CONCLUSION: Frail patients treated with PVd demonstrated a higher ORR and a longer PFS and DoT vs. Vd, despite a higher frequency of grade ≥ 3 TEAEs leading to pomalidomide, bortezomib, and/or dexamethasone discontinuation. Therefore, PVd treatment may improve patient outcomes, regardless of frailty.PMID:38072743 | DOI:10.1016/j.clml.2023.10.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 10, 2023 Category: Cancer & Oncology Authors: Albert Oriol Meletios Dimopoulos Fredrik Schjesvold Meral Beksac Thierry Facon Sujith Dhanasiri Shien Guo Yutian Mu Kevin Hong Christian Gentili Monica Galli Munci Yagci Alessandra Larocca Paul Richardson Katja Weisel Source Type: research
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
CONCLUSION: Frail patients treated with PVd demonstrated a higher ORR and a longer PFS and DoT vs. Vd, despite a higher frequency of grade ≥ 3 TEAEs leading to pomalidomide, bortezomib, and/or dexamethasone discontinuation. Therefore, PVd treatment may improve patient outcomes, regardless of frailty.PMID:38072743 | DOI:10.1016/j.clml.2023.10.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 10, 2023 Category: Cancer & Oncology Authors: Albert Oriol Meletios Dimopoulos Fredrik Schjesvold Meral Beksac Thierry Facon Sujith Dhanasiri Shien Guo Yutian Mu Kevin Hong Christian Gentili Monica Galli Munci Yagci Alessandra Larocca Paul Richardson Katja Weisel Source Type: research
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
CONCLUSION: Frail patients treated with PVd demonstrated a higher ORR and a longer PFS and DoT vs. Vd, despite a higher frequency of grade ≥ 3 TEAEs leading to pomalidomide, bortezomib, and/or dexamethasone discontinuation. Therefore, PVd treatment may improve patient outcomes, regardless of frailty.PMID:38072743 | DOI:10.1016/j.clml.2023.10.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 10, 2023 Category: Cancer & Oncology Authors: Albert Oriol Meletios Dimopoulos Fredrik Schjesvold Meral Beksac Thierry Facon Sujith Dhanasiri Shien Guo Yutian Mu Kevin Hong Christian Gentili Monica Galli Munci Yagci Alessandra Larocca Paul Richardson Katja Weisel Source Type: research
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
CONCLUSION: Frail patients treated with PVd demonstrated a higher ORR and a longer PFS and DoT vs. Vd, despite a higher frequency of grade ≥ 3 TEAEs leading to pomalidomide, bortezomib, and/or dexamethasone discontinuation. Therefore, PVd treatment may improve patient outcomes, regardless of frailty.PMID:38072743 | DOI:10.1016/j.clml.2023.10.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 10, 2023 Category: Cancer & Oncology Authors: Albert Oriol Meletios Dimopoulos Fredrik Schjesvold Meral Beksac Thierry Facon Sujith Dhanasiri Shien Guo Yutian Mu Kevin Hong Christian Gentili Monica Galli Munci Yagci Alessandra Larocca Paul Richardson Katja Weisel Source Type: research
Transcriptomic correlates of cell cycle checkpoints with distinct prognosis, molecular characteristics, immunological regulation, and therapeutic response in colorectal adenocarcinoma
ConclusionThe novel CCC signature exhibited a good ability for prognosis prediction for COAD patients, and the CCC score was found to be highly correlated with molecular features, immune-related characteristics, and therapeutic responses, which would greatly promote clinical management and precision medicine for COAD. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - December 8, 2023 Category: Allergy & Immunology Source Type: research
Neuropathy, Its Profile and Experimental Nerve Injury Neuropathic Pain Models: A Review
Curr Pharm Des. 2023 Dec 6. doi: 10.2174/0113816128274200231128065425. Online ahead of print.ABSTRACTNeuropathy is a terrible disorder that has a wide range of etiologies. Drug-induced neuropathy, which happens whenever a chemical agent damages the peripheral nerve system, has been linked here to the iatrogenic creation of some drugs. It is potentially permanent and causes sensory impairments and paresthesia that typically affects the hands, feet, and stockings; motor participation is uncommon. It might appear suddenly or over time, and the long-term outlook varies. The wide range of chronic pain conditions experienced by ...
Source: Current Pharmaceutical Design - December 7, 2023 Category: Drugs & Pharmacology Authors: Krishana Kumar Sharma Nishat Fatima Zeeshan Ali Mohd Moshin Phool Chandra Anurag Verma Omprakash Goshain Gajendra Kumar Source Type: research
Neuropathy, Its Profile and Experimental Nerve Injury Neuropathic Pain Models: A Review
Curr Pharm Des. 2023 Dec 6. doi: 10.2174/0113816128274200231128065425. Online ahead of print.ABSTRACTNeuropathy is a terrible disorder that has a wide range of etiologies. Drug-induced neuropathy, which happens whenever a chemical agent damages the peripheral nerve system, has been linked here to the iatrogenic creation of some drugs. It is potentially permanent and causes sensory impairments and paresthesia that typically affects the hands, feet, and stockings; motor participation is uncommon. It might appear suddenly or over time, and the long-term outlook varies. The wide range of chronic pain conditions experienced by ...
Source: Current Pharmaceutical Design - December 7, 2023 Category: Drugs & Pharmacology Authors: Krishana Kumar Sharma Nishat Fatima Zeeshan Ali Mohd Moshin Phool Chandra Anurag Verma Omprakash Goshain Gajendra Kumar Source Type: research
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival
ConclusionThe prognostic significance for the number of immune markers is only seen in the PVd arm and none of these immune markers exhibit prognostic values in the Vd arm. This study demonstrates the importance of the immunomodulatory effects and the therapeutic benefit of adding pomalidomide to Vd treatment. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - December 4, 2023 Category: Cancer & Oncology Source Type: research
Exploring the time-dependent regulatory potential of microRNAs in breast cancer cells treated with proteasome inhibitors
CONCLUSIONS: The diversity of pathways predicted to be affected by the diversity in miRNA expression after treatment with PIs paves the way for the recognition of new regulatory axes in BrCa.PMID:38038871 | DOI:10.1007/s12094-023-03349-5 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 1, 2023 Category: Cancer & Oncology Authors: Katerina Katsaraki Christos K Kontos Gerasimos Ardavanis-Loukeris Alexandros A Tzovaras Diamantis C Sideris Andreas Scorilas Source Type: research
Exploring the time-dependent regulatory potential of microRNAs in breast cancer cells treated with proteasome inhibitors
CONCLUSIONS: The diversity of pathways predicted to be affected by the diversity in miRNA expression after treatment with PIs paves the way for the recognition of new regulatory axes in BrCa.PMID:38038871 | DOI:10.1007/s12094-023-03349-5 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - December 1, 2023 Category: Cancer & Oncology Authors: Katerina Katsaraki Christos K Kontos Gerasimos Ardavanis-Loukeris Alexandros A Tzovaras Diamantis C Sideris Andreas Scorilas Source Type: research
Exploring the time-dependent regulatory potential of microRNAs in breast cancer cells treated with proteasome inhibitors
CONCLUSIONS: The diversity of pathways predicted to be affected by the diversity in miRNA expression after treatment with PIs paves the way for the recognition of new regulatory axes in BrCa.PMID:38038871 | DOI:10.1007/s12094-023-03349-5 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 1, 2023 Category: Cancer & Oncology Authors: Katerina Katsaraki Christos K Kontos Gerasimos Ardavanis-Loukeris Alexandros A Tzovaras Diamantis C Sideris Andreas Scorilas Source Type: research
